Filing Details

Accession Number:
0000914190-18-000137
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-04-12 16:11:29
Reporting Period:
2018-04-10
Accepted Time:
2018-04-12 16:11:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1196298 Nephros Inc NEPH Surgical & Medical Instruments & Apparatus (3841) 133971809
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1698052 Andrew Astor C/O Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Chief Financial Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-04-10 80,000 $0.45 420,459 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Warrants (right to buy) $0.30 2017-03-17 2022-03-17 166,666 166,666 Direct
Common Stock Stock Option (right to buy) $0.46 2027-02-13 289,785 289,785 Direct
Common Stock Stock Option (right to buy) $0.29 2027-05-01 209,355 209,355 Direct
Common Stock Stock Option (right to buy) $0.50 2027-12-20 50,000 50,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2022-03-17 166,666 166,666 Direct
2027-02-13 289,785 289,785 Direct
2027-05-01 209,355 209,355 Direct
2027-12-20 50,000 50,000 Direct
Footnotes
  1. Includes 120,417 shares of restricted stock that vest on 6/20/18.
  2. On 2/13/17, the Reporting Person was granted an option to purchase up to 579,571 shares of common stock of the Company. 12.5% of the shares subject to the option (relating to a total of 72,446 shares) vested on 2/13/18; 37.5% of the shares subject to the option (relating to a total of 217,339 shares) vest quarterly in 12 equal amounts, commencing on 5/13/18; 20% of the shares subject to the option (relating to a total of 115,914 shares) will vest, if ever, upon approval of listing of the Company's common stock on the Nasdaq Stock Market, New York Stock Exchange or such other national securities exchange approved by the Board; 10% of the shares subject to the option (relating to a total of 57,957 shares) will vest, if ever, on the February 1st following the Company's first completed fiscal year in which annual revenue exceeds $6,000,000; (continued)
  3. and 20% of the shares subject to the option (relating to a total of 115,914 shares) will vest, if ever, on the February 1st following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000.
  4. On 5/1/17, the Reporting Person was granted an option to purchase up to 418,709 shares of common stock of the Company. 12.5% of the shares subject to the option (relating to a total of 52,339 shares) vest on 5/1/18; 37.5% of the shares subject to the option (relating to a total of 157,016 shares) vest quarterly in 12 equal amounts, commencing on 7/1/18; 10% of the shares subject to the option (relating to a total of 41,871 shares) will vest, if ever, on the February 1st following the Company's first completed fiscal year in which annual revenue exceeds (continued)
  5. $6,000,000; 20% of the shares subject to the option (relating to a total of 83,742 shares) will vest, if ever, on the February 1st following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000; and 20% (relating to a total of 83,742 shares) will vest, if ever, upon approval of listing of the Company's common stock on the Nasdaq Stock Market, New York Stock Exchange or such other national securities exchange approved by the Board.
  6. On 12/20/17, the Reporting Person was granted an option to purchase 50,000 shares of common stock of the Company. 25% of the shares subject to the option (relating to a total of 12,500 shares) vest on 12/20/18 and the remaining 75% of the shares subject to the option (relating to a total of 37,500 shares) vest quarterly in 12 equal amounts, commencing on 3/20/19.